Clinical Trial Update: Faslodex Post Marketing Surveillance

View source ↗

Summary

A post-marketing surveillance trial evaluating Faslodex (fulvestrant) in breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Status: COMPLETED